BRAIDWELL LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001920938
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 65 positions · Total reported value $2.39B · Top-10 concentration 38.8% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 75.0% · 24 new · 32 cut · 25 exited
Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +24.0% · vs SPY +9.2% · Prev Value $2.64B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2024 13F filing, BRAIDWELL LP disclosed 65 equity positions with a combined reported value of $2.39B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 38.8% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were NVCR ($129.79M), NBIX ($104.49M), CGON ($104.48M). By sector, the heaviest allocations are Health Care 84.5%, Industrials 1.6%. Versus the prior quarter, allocation shifted toward Other (+0.6pp), Industrials (+0.5pp) and away from Health Care (-1.1pp).
Versus the prior quarter, BRAIDWELL LP opened 24 new positions, trimmed 32 and fully exited 25, a turnover rate of 75.0% of positions. The portfolio's overlap with the prior quarter was 62% of names.
The largest new positions opened in Q2 2024 were EXAS ($48.24M), IMCR ($27.02M), AKRO ($25.44M).
Of the 25 positions fully exited versus the prior quarter, the largest were HSCS ($133.11M), INSM ($69.43M), KPTI ($35.79M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- EXAS EXACT SCIENCES CORP · $48.24M
- IMCR IMMUNOCORE HLDGS PLC · $27.02M
- AKRO AKERO THERAPEUTICS INC · $25.44M
- APLS APELLIS PHARMACEUTICALS INC · $23.47M
- ATEC ALPHATEC HLDGS INC · $22.94M
- LXRX LEXICON PHARMACEUTICALS INC · $13.94M
- ARVN ARVINAS INC · $13.77M
- OCUL OCULAR THERAPEUTIX INC · $11.24M
Fully Exited (vs previous quarter)
- HSCS HEARTSCIENCES INC · prev qtr: $133.11M
- INSM INSMED INC · prev qtr: $69.43M
- KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $35.79M
- TRML TOURMALINE BIO INC · prev qtr: $20.77M
- BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $19.12M
- GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $18.68M
- BCRX BIOCRYST PHARMACEUTICALS INC · prev qtr: $17.17M
- ITOS ITEOS THERAPEUTICS INC · prev qtr: $15.85M
Insider Transactions (Form 4)
Latest BRAIDWELL LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Braidwell LP, based in Stamford, CT, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 83 positions worth $2.54B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: STAMFORD, CT, United States
- SEC registration: 801-122966 (status: Approved), registered 2022-01-03
- Regulatory AUM (Form ADV): $3.63B as of 2026-09-22
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 12 private funds, of which 11 hedge funds
- Website: braidwell.com
Portfolio Structure
- 83 positions · $2.54B reported value (Q2 2026)
- Top 10 holdings = 32.8% of reported value
- Largest position: CAI (CARIS LIFE SCIENCES INC) at 5.8%
- Average position size: $30.62M
Sector Tilt
- Health Care 90.1%
- Information Technology 4.3%
- Industrials 4.3%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 24 new, 21 added, 32 reduced, 25 exited
- 6 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
140.83M | $129.79M | 5.44% | Add | |
| 2 |
|
759.01K | $104.49M | 4.38% | Add | |
| 3 |
|
3.31M | $104.48M | 4.38% | Add | |
| 4 |
|
2.56M | $99.84M | 4.18% | Add | |
| 5 |
|
2.39M | $94.13M | 3.94% | Add | |
| 6 |
|
116.38M | $90.85M | 3.81% | Add | |
| 7 |
|
2.81M | $81.09M | 3.40% | Add | |
| 8 |
|
68.00M | $74.41M | 3.12% | Add | |
| 9 |
|
1.67M | $73.95M | 3.10% | Add | |
| 10 |
|
73.50M | $73.78M | 3.09% | Add | |
| 11 |
|
166.92K | $71.78M | 3.01% | Reduce | |
| 12 |
|
275.21K | $66.44M | 2.78% | Add | |
| 13 |
|
9.02M | $64.61M | 2.71% | Add | |
| 14 |
|
808.30K | $61.03M | 2.56% | Reduce | |
| 15 |
|
2.51M | $59.12M | 2.48% | Add | |
| 16 |
|
496.58K | $58.77M | 2.46% | Add | |
| 17 |
|
1.11M | $58.68M | 2.46% | Add | |
| 18 |
|
526.36K | $56.66M | 2.37% | Add | |
| 19 |
|
379.44K | $50.78M | 2.13% | Add | |
| 20 |
|
56.03M | $48.83M | 2.05% | Hold | |
| 21 |
|
1.14M | $48.24M | 2.02% | New | |
| 22 |
|
982.21K | $44.89M | 1.88% | Add | |
| 23 |
|
100.50K | $44.71M | 1.87% | Hold | |
| 24 |
|
3.04M | $41.83M | 1.75% | Add | |
| 25 |
|
323.51K | $40.78M | 1.71% | Add | |
| 26 |
|
2.90M | $40.75M | 1.71% | Add | |
| 27 |
|
70.45K | $38.96M | 1.63% | Add | |
| 28 |
|
2.06M | $38.43M | 1.61% | Add | |
| 29 |
|
212.59K | $38.26M | 1.60% | Reduce | |
| 30 |
|
1.11M | $31.86M | 1.33% | Hold | |
| 31 |
|
4.44M | $28.94M | 1.21% | Reduce | |
| 32 |
|
189.96K | $28.61M | 1.20% | Reduce | |
| 33 |
|
4.15M | $28.39M | 1.19% | Add | |
| 34 |
|
797.27K | $27.02M | 1.13% | New | |
| 35 |
|
1.08M | $25.44M | 1.07% | New | |
| 36 |
|
611.80K | $23.47M | 0.98% | New | |
| 37 |
|
2.19M | $22.94M | 0.96% | New | |
| 38 |
|
1.38M | $22.17M | 0.93% | Add | |
| 39 |
|
107.18K | $19.68M | 0.82% | Reduce | |
| 40 |
|
3.01M | $19.60M | 0.82% | Reduce | |
| 41 |
|
1.70M | $14.30M | 0.60% | Reduce | |
| 42 |
|
8.29M | $13.94M | 0.58% | New | |
| 43 |
|
517.23K | $13.77M | 0.58% | New | |
| 44 |
|
81.90K | $12.94M | 0.54% | Reduce | |
| 45 |
|
1.47M | $11.76M | 0.49% | Add | |
| 46 |
|
1.64M | $11.24M | 0.47% | New | |
| 47 |
|
2.38M | $10.81M | 0.45% | Hold | |
| 48 |
|
11.50M | $10.37M | 0.43% | Reduce | |
| 49 |
|
5.12M | $9.83M | 0.41% | New | |
| 50 |
|
173.90K | $9.53M | 0.40% | New | |
FAQ
What did BRAIDWELL LP buy in 2024-Q2?
In its 2024-Q2 13F filing, BRAIDWELL LP reported 65 equity positions worth $2.39B in aggregate; its largest disclosed positions were NVCR ($129.79M), NBIX ($104.49M), CGON ($104.48M).
How large is BRAIDWELL LP's portfolio?
BRAIDWELL LP reported $2.39B of long equity holdings across 65 positions as of 2024-Q2. Top-10 holdings account for 38.8% of reported value.
What is BRAIDWELL LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.